Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Nuvalent (NUVL) and Innoviva (INVA)

Tipranks - Tipranks - Thu Apr 9, 7:30AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD), Nuvalent (NUVL) and Innoviva (INVA) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Gilead Sciences (GILD)

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Gilead Sciences today and set a price target of $165.00. The company’s shares closed last Tuesday at $138.80.

According to TipRanks.com, Biegler is a 4-star analyst with an average return of 6.4% and a 41.3% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, BridgeBio Oncology Therapeutics, and Day One Biopharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $158.79 average price target, implying a 14.2% upside from current levels. In a report issued on March 24, Scotiabank also maintained a Buy rating on the stock with a $177.00 price target.

See today’s best-performing stocks on TipRanks >>

Nuvalent (NUVL)

Wedbush analyst David Nierengarten maintained a Buy rating on Nuvalent today and set a price target of $125.00. The company’s shares closed last Tuesday at $102.25.

According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 15.3% and a 48.3% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Perspective Therapeutics, and Kiniksa Pharmaceuticals. ;'>

Nuvalent has an analyst consensus of Strong Buy, with a price target consensus of $140.93, which is a 35.9% upside from current levels. In a report issued on March 25, Canaccord Genuity also maintained a Buy rating on the stock with a $126.00 price target.

Innoviva (INVA)

Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Innoviva yesterday and set a price target of $32.00. The company’s shares closed last Tuesday at $23.28.

According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 9.9% and a 43.1% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, NewAmsterdam Pharma Company, and Apellis Pharmaceuticals. ;'>

Innoviva has an analyst consensus of Strong Buy, with a price target consensus of $37.00.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).